FDA Center for Drug Evaluation & Research Issues Warning Letter to Harbin Jixianglong Biotech
May 20, 2026
May 20, 2026
WASHINGTON, May 20 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Harbin Jixianglong Biotech Co. Ltd. from its Center for Drug Evaluation and Research:
* * *
Recipient: Mr. Guo Qing Leng, President and General Manager, Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Hulan Qu Harbin Shi Heilongjiang Sheng, 150025, China
Issuing Office: Center for Dru . . .
* * *
Recipient: Mr. Guo Qing Leng, President and General Manager, Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Hulan Qu Harbin Shi Heilongjiang Sheng, 150025, China
Issuing Office: Center for Dru . . .